Short Interest in Valeant Pharmaceuticals Intl Rises By 166.3% (VRX)
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 10,358,313 shares, a growth of 166.3% from the April 15th total of 3,889,779 shares, Stock Ratings News reports. Based on an average daily volume of 4,674,623 shares, the days-to-cover ratio is currently 2.2 days. Approximately 3.2% of the company’s shares are short sold.
In other Valeant Pharmaceuticals Intl news, EVP Robert Roswell Chai-Onn sold 10,000 shares of Valeant Pharmaceuticals Intl stock on the open market in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $130.08, for a total transaction of $1,300,800.00. Following the transaction, the executive vice president now directly owns 23,999 shares in the company, valued at approximately $3,121,790. The sale was disclosed in a legal filing with the SEC, which is available at this link.
VRX has been the subject of a number of recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research note on Friday, May 16th. They now have a $153.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $145.02.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 130.97 on Wednesday. Valeant Pharmaceuticals Intl has a 52-week low of $73.25 and a 52-week high of $153.10. The stock has a 50-day moving average of $128.9 and a 200-day moving average of $126.5. The company’s market cap is $43.910 billion.
Valeant Pharmaceuticals Intl (NYSE:VRX) last released its earnings data on Thursday, May 8th. The company reported $1.76 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.72 by $0.04. The company had revenue of $1.85 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company posted $1.30 earnings per share. The company’s quarterly revenue was up 76.6% on a year-over-year basis. Analysts expect that Valeant Pharmaceuticals Intl will post $8.74 EPS for the current fiscal year.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.